- XELOX (Xeloda(R) + Oxaliplatin) Shown To Be As Effective As Current Standard In The Treatment
Roche announced that the latest results from an international, Phase III study showed the chemotherapy combination XELOX (Xeloda + oxaliplatin) to be as effective -- in terms of progression-free survival (PFS) -- as the current standard treatment, FOLFOX-4 (infused 5-FU/leucovorin + oxaliplatin), in the treatment of advanced (metastatic) colorectal cancer. - Whole-Body Scans May Provide Option For Diagnosing Colorectal Cancer
Preliminary research suggests that whole-body PET and CT scans could provide a suitable method for diagnosing the stage of colorectal cancer, according to a study in the December 6 issue of JAMA. - When To Stop Screening For Colorectal Cancer? New Study Says No Need To Screen Older People
A study of people 67 years and older who were diagnosed with colon cancer found that those with three or more chronic diseases at the time of diagnosis had life expectancies of five years or less (Article, p. 646). Life expectancy was strongly related to both age and the burden of chronic illness. - What Cures Your Aches Might Prevent Cance
Mayo Clinic Cancer Center has begun three clinical studies looking at the use of nonsteroidal anti-inflammatory drugs (NSAIDs) to prevent cancer -- colon, esophageal or lung. - Vioxx Reduces The Risk Of Colorectal Polyps, Study Finds
A researcher from Dartmouth reports the results of a clinical trial that shows that the cyclooxygenase-2 (COX-2) inhibitor rofecoxib (VIOXX®) reduces the risk of colorectal adenomas, or polyps. Polyps are benign tumors that are precursors to colon cancer, and they are often found in older adults. - Vecibix Treatment For Patients With Metastatic Colorectal Cancer Approved By FDA
Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved VectibixTM (panitumumab) following priority review. Vectibix is the first entirely human monoclonal antibody for the treatment of patients with epidermal growth factor receptor- (EGFr) expressing metastatic colorectal cancer after disease progression on, or following fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens. - Unlocking Colon Cancer With Key Of Prevention
An international team of scientists reports that a single 400-milligram daily dose of celecoxib, commonly called Celebrex® and manufactured by Pfizer, significantly reduced recurrence of adenomas, or pre-malignant colon tumors - within three years of previous adenoma removal. - Survival Data Available From Two Randomized ERBITUX Studies In Metastatic Colorectal Cancer
ImClone Systems Incorporated (Nasdaq: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) today announced results from two randomized Phase III trials of ERBITUX(R) (cetuximab) in patients with metastatic colorectal cancer. These are the first large, randomized studies to examine the impact of ERBITUX treatment on overall survival in colon cancer. - Scientists Stop Colon Cancer Growth In Mice By Blocking Just One Enzyme
Texas researchers have discovered what may become a potent new weapon in the fight against colon cancer. - Prediction Models Help Identify Risk Of Gene Mutation Linked With Colorectal Cancer
Prediction models that incorporate certain personal and family medical history characteristics can help identify high-risk patients who are likely to have a gene mutation associated with a type of colorectal cancer, according to two studies in the September 27 issue of JAMA. - New Study Shows InSure(R) Colorectal Cancer Screening Test Significantly Better At Detecting Early
A study published in the journal CANCER found that InSure,(R) a Fecal Immunochemical Test (FIT) from Quest Diagnostics Incorporated (NYSE: DGX) detected three times as many early- stage colorectal cancers and nearly two times as many significant (pre- cancerous) adenomas compared to Hemoccult II Sensa(R)(1), the traditional guaiac fecal occult blood test.(2) - Model Predicts Colon Cancer Inheritable Genetic Defects
Researchers from the Johns Hopkins University and other institutions have developed a new prediction model for genetic defects known as Lynch syndrome, which predisposes families to develop colorectal cancer. The model, called MMRpro, is based on an individual's detailed family history of colorectal and endometrial cancer, as well as knowledge of how genetic mutations manifest themselves--in the form of tumors. - Looking For A Cancer Cure? Try The Spice Rack
In the last few years, that tactic has proved productive for researchers investigating turmeric, a curry spice used for centuries in Indian traditional medicine. - Iowa State Researchers Developing Software To Improve Colon Exams
Computer technology developed with the help of Iowa State University researchers will analyze videos of colon exams and should help doctors improve the colonoscopy procedure they use to look for cancer. - Increased Risk Of Colorectal Cancer With Low Folate Diets
A new study by scientists at the MUHC has revealed that a diet low in folate may increase the risk of developing colorectal cancer. Published in the scientific journal Cancer Research 2-Nov-2006, the study not only illustrates a way to prevent the disease but also provides further insight into the mechanisms of the disease, which could lead to novel therapies. - Guidelines For Advanced Colorectal Surgery Often Not Followed
The majority of patients with locally advanced colorectal cancer do not receive the extensive surgery to remove the cancer and adjacent tissues, a new study reports. This extensive surgery, called a multivisceral resection, is recommended by the National Cancer Institute and American Society of Colon and Rectal Surgeons because it reduces local recurrence and improves survival. - Growth Of Colorectal Tumors In Mice Checked By Grape Seed Extract And Cell Cycle Halted
Chemicals found in grape seeds significantly inhibited growth of colorectal tumors in both cell cultures and in mice, according to researchers who have already demonstrated the extract's anti-cancer effects in other tumor types. - Genetic Variation Impacts Aspirin's Effectiveness In Preventing Colon Cancer, Dartmouth Study Finds
Dartmouth researchers are among a team of doctors that have learned more about how people may or may not benefit from taking aspirin in the effort to curb colon cancer. - Effective Prevention Of Colorectal Cancer With Virtual Colonoscopy
Three-dimensional computed tomography (CT) colonography, also known as virtual colonoscopy, is an accurate screening method for colorectal cancer, according to a study published in the November issue of the journal Radiology. In addition, when covered by third-party payers, virtual colonoscopy may entice more people to be screened. - Dynavax Initiates Phase 1 Clinical Trial In Metastatic Colorectal Cancer
Dynavax Technologies Corporation (Nasdaq: DVAX) announced today the initiation of a Phase 1 dose escalation clinical trial of its TLR9 agonist in combination with a standard chemotherapeutic regimen for metastatic colorectal cancer. - Colorectal Cancer Screening Rates Studied
The rate of colorectal cancer screening appears to be increasing among Veterans Affairs patients, although use of colonoscopy is less common than other screening procedures, according to a report in the November 13 issue of Archives of Internal Medicine, one of the JAMA/Archives journals. - Cleveland Clinic Physicians Hold Symposium On Prevention, Diagnostic, And Surgical Treatment
Three Cleveland Clinic physicians will travel to Cancun, Mexico for the XXX Panamerican Congress of Gastroenterology, organized by the Mexican Association of Gastroenterology, to hold a symposium on prevention, diagnostic, and surgical treatment of colorectal cancer. The Congress, to be held November 12-15, 2006, at the Cancun Convention Center, will be attended by approximately 2500 gastroenterologists from around the world. - Aspirin Takers With A Genetic Variant May Have Lower Colorectal Adenoma Risk
A genetic variation (G315A) in the ODC gene may change a person's response to aspirin given for colorectal cancer prevention. - Annals Of Internal Medicine Tip Sheet For October 3, 2006, Issue
1. Medical Misdiagnoses in the Office Setting Are Caused by Multiple Breakdowns
A study of 181 closed malpractice claims in which patients alleged a missed or delayed diagnosis in an ambulatory setting found that 59 percent (106) of these errors were associated with serious harm and 30 percent (55) resulted in death (Article, p. 488). - ADVENTRX Completes Enrollment In CoFactor Phase IIb Metastatic Colorectal Cancer Trial
ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) announced today that it has completed patient enrollment in a Phase IIb clinical trial. The trial is designed to compare the safety and efficacy of 5-fluorouracil (5-FU) plus CoFactor(R) to 5-FU plus leucovorin in first line treatment of metastatic colorectal cancer. - A New Way To Treat Colon Cancer Could Be Three To Five Years Away
Researchers at University of Utah's Huntsman Cancer Institute have discovered a new target for possible future colon cancer treatments - a molecule that is implicated in 85 percent of colon cancer cases. - "Virtual" Colonoscopy Considerably More Expensive
Wake Forest University Baptist Medical Center researchers have found that "virtual" colonoscopy using a computer tomography (CT) scanner is considerably more expensive than the traditional procedure due to the detection of suspicious images outside of the colon.
|
